Follow BellaSeno for the latest company news, industry events, and regenerative medicine updates. Explore our latest media and announcements below.
Sign Up to Our Newsletter →
Following positive two-year human clinical data from its scaffold-guided regenerative program, BellaSeno has announced an exclusive global licensing agreement with Mentor Worldwide LLC, a Johnson & Johnson company.
This collaboration will bring together BellaSeno’s technology alongside the clinical, regulatory and commercial scale of one of the world’s leading healthcare companies. As breast aesthetics continues to evolve, there is growing demand for approaches that expand the range of solutions available to patients and surgeons. This collaboration will help accelerate the final clinical development of the breast scaffold platform as BellaSeno prepares for global market introduction.
New Clinical Data on BellaSeno’s Novel, Resorbable Breast Implants Presented at The Aesthetic MEET 2025
March 24, 2025
BellaSeno Successfully Completes Two Clinical Trials with Novel, Resorbable Breast Implants
January 14, 2025
Preliminary Data of BellaSeno’s Clinical Trial on Scaffold-Guided Breast Regeneration Presented at the 93rd Annual Plastic Surgery Meeting in San Diego, CA
October 9, 2024
BellaSeno Reports Positive Interim Findings of Australian Clinical Trials in Breast Scaffold Patients
June 12, 2024
.jpg)
Funding to support establishment of the world´s first fully automated production facility for resorbable medical scaffolds based in Australia
June 5, 2024
BellaSeno’s regenerative scaffold platform has been featured across international media, clinical discussions, and industry publications as interest grows in the future of soft-tissue restoration and scaffold-guided regeneration.
Deutscher Platz 5A
04103 Leipzig
Germany
4 Starling Street
Burliegh Heads
QLD, Australia, 4220
